SEM Biotech expands blood collection tube production

SEM Biotech has announced a major step in the development of its medical manufacturing operations, establishing an automated production platform for vacuum blood collection tubes under the Vacusem brand. The platform has an annual production capacity of 500 million tubes and operates in an ISO Class 8 cleanroom environment. According to the company, production is organized in line with high hygiene standards and focuses on consistent quality, repeatability and compliance with European Union market requirements. SEM Biotech describes the investment as part of its plan to build a technology-driven medical manufacturing brand serving European and international markets. The company states that the platform is designed to support industrial-scale production of medical components with process stability, traceability and controlled production conditions.

Strategic collaboration with Husky Technologies

The investment is based on a strategic collaboration with Husky Technologies, described by SEM Biotech as its long-term technology partner. Husky Technologies is identified in the source material as a global supplier of precision injection molding solutions and services. SEM Biotech states that high-volume medical manufacturing requires more than individual machines, pointing to the need for a proven, fully integrated production platform, single-source system responsibility and technical support throughout the lifecycle of the investment.

At the center of the production platform is Husky’s Ichor integrated medical system, built on the company’s PET processing technology. The system is combined with advanced Schöttli medical molds intended for precision and consistent high-volume medical production. The platform also includes integrated robotics and auxiliary equipment, hot-runner technology, a unified operator interface and Husky Advantage+Elite proactive monitoring support.

Integrated production platform

According to SEM Biotech, the integrated architecture is intended to reduce production complexity, increase throughput, minimize material waste and variability, and support full traceability and process stability. The company states that this provides a scalable and reliable basis for producing consistently high-quality medical components at industrial volumes.

Husky’s role in the project covers not only manufacturing technology, but also system engineering, application expertise, operator training and long-term service support. SEM Biotech states that the ability to combine the injection molding machine, Schöttli mold technology, hot runners, controllers, auxiliaries and monitoring services within a single integrated solution was a decisive factor in the technology selection.

"When human health is concerned, no compromise is acceptable."

Focus on medical manufacturing in Türkiye

SEM Biotech states that its objective is not limited to manufacturing blood collection tubes. The company points to the combination of advanced engineering, a strict quality culture, responsible production and leading technologies as the basis for building a medical brand focused on human health in its region.

The collaboration with Husky Technologies and Schöttli is presented by SEM Biotech as a shared commitment to precision, safety, reliability and quality. The company states that the partners are creating a medical manufacturing platform in Türkiye positioned to serve European and international markets.